NCT05799118 Study of the Role of Genetic Modifiers in Hemoglobinopathies
| NCT ID | NCT05799118 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cyprus Institute of Neurology and Genetics |
| Condition | Sickle Cell Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 30,000 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30,000 participants in total. It began in 2022-10-01 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered. * Age ≥ 2 years old at the time of the collection of the phenotypic data. * There will be no limits on study participants in terms of gender, ethnicity, morbidities. Exclusion Criteria: * Patients treated with stem cell transplantation or genetic therapy. * Age \< 2 years old at the time of the collection of the phenotypic data. * Patient or legal representative for minors unwilling or unable to give consent.
Contact & Investigator
Petros Kountouris, PhD
PRINCIPAL INVESTIGATOR
Cyprus Institute of Neurology and Genetics
Frequently Asked Questions
Who can join the NCT05799118 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05799118 currently recruiting?
Yes, NCT05799118 is actively recruiting participants. Contact the research team at admin@inherentnetwork.org for enrollment information.
Where is the NCT05799118 trial being conducted?
This trial is being conducted at Boston, United States, Luanda, Angola, Buenos Aires, Argentina, Leuven, Belgium and 11 additional locations.
Who is sponsoring the NCT05799118 clinical trial?
NCT05799118 is sponsored by Cyprus Institute of Neurology and Genetics. The principal investigator is Petros Kountouris, PhD at Cyprus Institute of Neurology and Genetics. The trial plans to enroll 30,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.